ReviewOncoTargets and therapy2016

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.

Jun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.